

Study / Protocol	Drug(s)	NCT Number	ClinicalTrials.gov Link	Protocol Summary
BA39731 - Verismo	Ocrelizumab & other DMT's	Registry	N/A	An Observational Study of Ocrelizumab Treated Patients With Multiple Sclerosis to Determine The Incidence and Mortality Rates of Breast Cancer and All Malignancies (VERISMO Study)
BN42082 - Musette	Ocrelizumab	NCT04544436	<a href="https://clinicaltrials.gov/study/NCT04544436?cond=Multiple%20Sclerosis&amp;intr=ocrelizumab%20&amp;term=BN42082&amp;rank=1">https://clinicaltrials.gov/study/NCT04544436?cond=Multiple%20Sclerosis&amp;intr=ocrelizumab%20&amp;term=BN42082&amp;rank=1</a>	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
CLOU064C12302 - Remodel III*	Remibrutinib / Teriflunomide	NCT05156281	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT05156281?term=Remibrutinib&amp;draw=2&amp;rank=6">https://classic.clinicaltrials.gov/ct2/show/NCT05156281?term=Remibrutinib&amp;draw=2&amp;rank=6</a>	A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib
COMB157G2399	Ofatumumab	NCT03650114	<a href="https://clinicaltrials.gov/study/NCT03650114?cond=Multiple%20Sclerosis&amp;term=COMB157G2399%20&amp;rank=1">https://clinicaltrials.gov/study/NCT03650114?cond=Multiple%20Sclerosis&amp;term=COMB157G2399%20&amp;rank=1</a>	Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)
COMB157GUS07 - OLIKOS	Ofatumumab / anti-CD20 therapies	NCT04486716	<a href="https://clinicaltrials.gov/study/NCT04486716?cond=Multiple%20Sclerosis&amp;intr=ocrelizumab%20&amp;term=COMB157GUS07&amp;rank=1">https://clinicaltrials.gov/study/NCT04486716?cond=Multiple%20Sclerosis&amp;intr=ocrelizumab%20&amp;term=COMB157GUS07&amp;rank=1</a>	A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis (OLIKOS)
COMB157GUS09 - SOSTOS*	Ofatumumab	NCT05090371	<a href="https://clinicaltrials.gov/study/NCT05090371?cond=Multiple%20Sclerosis&amp;term=COMB157GUS09&amp;rank=1">https://clinicaltrials.gov/study/NCT05090371?cond=Multiple%20Sclerosis&amp;term=COMB157GUS09&amp;rank=1</a>	A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NFL) Elevation (SOSTOS)
COMB157GUS10 - AGNOS*	Ofatumumab - Treatment Naïve	NCT05084638	<a href="https://clinicaltrials.gov/study/NCT05084638?cond=Multiple%20Sclerosis&amp;term=COMB157GUS10&amp;rank=1">https://clinicaltrials.gov/study/NCT05084638?cond=Multiple%20Sclerosis&amp;term=COMB157GUS10&amp;rank=1</a>	Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)
EFC16034 - Gemini	Teriflunomide / Tolebrutinib	NCT04410991	<a href="https://clinicaltrials.gov/study/NCT04410991?cond=Multiple%20Sclerosis&amp;term=EFC16034&amp;rank=1">https://clinicaltrials.gov/study/NCT04410991?cond=Multiple%20Sclerosis&amp;term=EFC16034&amp;rank=1</a>	Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
EFC17504	Frexalimab / Placebo	Upcoming	Upcoming	A Phase 3 randomized, double-blind, efficacy and safety study comparing frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis
EFC17919	Frexalimab / Aubagio	Upcoming	Upcoming	A phase 3, randomized, double blind efficacy and safety studies comparing frexalimab (SAR441344) to teriflunomide (Aubagio®) in adult participants with relapsing forms of multiple sclerosis
GN41791 - Fentrepid	Fenebrutinib / Ocrelizumab	NCT04544449	<a href="https://clinicaltrials.gov/study/NCT04544449?cond=Multiple%20Sclerosis&amp;term=GN41791&amp;rank=1">https://clinicaltrials.gov/study/NCT04544449?cond=Multiple%20Sclerosis&amp;term=GN41791&amp;rank=1</a>	A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENTrepid)
GN42272 - Fenhance*	Fenebrutinib / Teriflunomide	NCT04586023	<a href="https://clinicaltrials.gov/study/NCT04586023?cond=Multiple%20Sclerosis&amp;term=GN42272&amp;rank=1">https://clinicaltrials.gov/study/NCT04586023?cond=Multiple%20Sclerosis&amp;term=GN42272&amp;rank=1</a>	Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance 2)
J3K-MC-KIAB	LY3541860 / Placebo	Upcoming	Upcoming	An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
LTS16004	Tolebrutinib	NCT03996291	<a href="https://clinicaltrials.gov/study/NCT03996291?cond=Multiple%20Sclerosis&amp;term=LTS16004&amp;rank=1">https://clinicaltrials.gov/study/NCT03996291?cond=Multiple%20Sclerosis&amp;term=LTS16004&amp;rank=1</a>	Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
MN43964 - OLERO	Ocrelizumab	NCT05269004	<a href="https://clinicaltrials.gov/study/NCT05269004?cond=Multiple%20Sclerosis&amp;term=MN43964&amp;rank=1">https://clinicaltrials.gov/study/NCT05269004?cond=Multiple%20Sclerosis&amp;term=MN43964&amp;rank=1</a>	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)
OBS13434 - PASS	Lemtrada	Registry	N/A	A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
PTI-307-201 - Pipeline	Pipe-307	Upcoming	Upcoming	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 as an Adjunctive Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis followed by a Dose-Blinded Study Extension
RPC-1063-MS-001 - Enlighten	Ozanimod	NCT04140305	<a href="https://clinicaltrials.gov/study/NCT04140305?cond=Multiple%20Sclerosis&amp;term=RPC-1063-MS-001&amp;rank=1">https://clinicaltrials.gov/study/NCT04140305?cond=Multiple%20Sclerosis&amp;term=RPC-1063-MS-001&amp;rank=1</a>	Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)
RPC-1063-MS-010 - Vaccine*	Ozanimod / Influenza Vaccine	NCT05028634	<a href="https://clinicaltrials.gov/study/NCT05028634?cond=Multiple%20Sclerosis&amp;term=RPC-1063-MS-010&amp;rank=1">https://clinicaltrials.gov/study/NCT05028634?cond=Multiple%20Sclerosis&amp;term=RPC-1063-MS-010&amp;rank=1</a>	Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
TG1101- RMS303	Ublituximab	NCT03381170	<a href="https://clinicaltrials.gov/study/NCT03381170?cond=Multiple%20Sclerosis&amp;term=TG1101-%20RMS303&amp;rank=1">https://clinicaltrials.gov/study/NCT03381170?cond=Multiple%20Sclerosis&amp;term=TG1101-%20RMS303&amp;rank=1</a>	An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201 Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis
TG1101-RMS401 - Enhance*	Ublituximab	NCT05877963	<a href="https://clinicaltrials.gov/study/NCT05877963?cond=Multiple%20Sclerosis&amp;term=TG1101-RMS401&amp;rank=1">https://clinicaltrials.gov/study/NCT05877963?cond=Multiple%20Sclerosis&amp;term=TG1101-RMS401&amp;rank=1</a>	Study to Evaluate the Maintenance of Efficacy When Transitioning From Anti-CD20 Therapy to Ublituximab (ENHANCE)

\*Currently Enrolling New Patients